Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (424)	6/1/2000 6:54:00 PM
From: Miljenko Zuanic	Respond to of 1169

<<Xenova also has a series of Phase IIa trials nearing completion with its P-glycoprotein pump (P-gp) inhibitor, XR9576. Positive interim PK data from the XR9576/paclitaxel and XR9576/doxorubicin combination trials were announced in March and May 2000 respectively. Early indications from the paclitaxel trial have indicated a response rate to date greater than that which might have been expected from patients administered paclitaxel alone. Data from several of the patients enrolled in the third study, (XR9576/vinorelbine) who have received a medical imaging agent, sestamibi, with and without XR9576, have shown that administration of a single iv infusion of XR9576 results in inhibition of P-gp in the liver for periods of up to 48 hours. Inhibition of P-gp with XR9576 is being developed with the objective of enhancing the effectiveness of existing cytotoxics in patients with drug-resistant cancer. As reported by the company in March 2000, it is expected that XR9576 will be ready to enter pivotal Phase III trials before the end of this calendar year. >> Aren't we about to hear something on INCEL frontier? From my previous post: <<If I do not believe in VRTX capability, this deal will be at half value (for me), as it is presented.>> After reading full kinases agreement I must correct myself. Kinases deal is much stronger for VRTX than it was my first impression from CC. Miljenko